Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression

Area of Science:

• Pharmacogenomics
• Clinical Psychiatry
• Geriatric Medicine

Background:

• Major depressive disorder (MDD) is a significant health concern in older adults.
• Antidepressant medication failure is common, necessitating alternative treatment strategies.
• Personalized medicine approaches, like pharmacogenomics, offer potential for optimizing treatment selection.

Purpose of the Study:

• To evaluate the clinical utility of combinatorial pharmacogenomic testing for guiding antidepressant selection in older adults with MDD.
• To compare outcomes between pharmacogenomic-guided care and treatment as usual (TAU) in this population.

Main Methods:

• A post hoc analysis of a randomized controlled trial involving 206 adults aged 65+ with MDD and prior treatment failure.
• Participants received either combinatorial pharmacogenomic testing to inform medication selection (guided-care) or TAU.
• Outcomes measured at week 8 included symptom improvement, response, and remission rates using the Hamilton Depression Rating Scale.

Main Results:

• Guided-care demonstrated significantly improved response (13.6% increase) and remission (12.7% increase) rates compared to TAU at week 8.
• Symptom improvement was not significantly different between groups.
• Twice as many patients in guided-care received medications with no predicted gene-drug interactions.
• Benefits observed in guided-care were durable through 24 weeks and not impacted by comorbidities.

Conclusions:

• Combinatorial pharmacogenomic testing can effectively inform medication selection in older adults with treatment-resistant MDD.
• This personalized approach leads to better treatment response and remission rates.
• Pharmacogenomic guidance offers a durable and effective strategy for managing depression in the elderly.